Literature DB >> 16291282

Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population.

Gary Ong1, Kee Tai Goh, Stefan Ma, Suok Kai Chew.   

Abstract

OBJECTIVE: The comparative efficacy of the three mumps vaccine strains (Jeryl-Lynn, Urabe and Rubini) was conducted in an Asian population from data arising from an epidemiological investigation of seven institutional outbreaks of mumps in Singapore.
METHODS: Demographic information (gender, age, ethnic group), clinical presentation and vaccination history (date and place of mumps vaccination, type of mumps vaccine received) of all children who attended the six childcare centres and one primary school where outbreaks of 20 or more cases of mumps occurred in 1999 were collected. The attack rate of the unvaccinated group and the attack rates of the vaccine groups (for each vaccine strain) were determined and the vaccine efficacy of the three vaccines calculated.
RESULTS: The vaccine efficacy of the Jeryl-Lynn strain, Urabe strain and Rubini strain mumps vaccine were 80.7, 54.4 and -55.3%, respectively.
CONCLUSION: Rubini strain mumps vaccine conferred no protection and has since been deregistered in Singapore.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16291282     DOI: 10.1016/j.jinf.2004.10.001

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  13 in total

1.  Recent mumps outbreaks in vaccinated populations: no evidence of immune escape.

Authors:  Steven A Rubin; Malen A Link; Christian J Sauder; Cheryl Zhang; Laurie Ngo; Bert K Rima; W Paul Duprex
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Factors influencing preclinical in vivo evaluation of mumps vaccine strain immunogenicity.

Authors:  B Halassy; T Kurtović; M Brgles; M Lang Balija; D Forčić
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Safety and immunogenicity of a live attenuated mumps vaccine: a phase I clinical trial.

Authors:  Yan Liang; Jingchen Ma; Changgui Li; Yuguo Chen; Longding Liu; Yun Liao; Ying Zhang; Li Jiang; Xuan-Yi Wang; Yanchun Che; Wei Deng; Hong Li; Xiaoyu Cui; Na Ma; Dong Ding; Zhongping Xie; Pingfang Cui; Qiuyan Ji; JingJing Wang; Yuliang Zhao; Junzhi Wang; Qihan Li
Journal:  Hum Vaccin Immunother       Date:  2014-03-10       Impact factor: 3.452

Review 4.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

5.  Close the gap for routine mumps vaccination in Japan.

Authors:  Taito Kitano
Journal:  Hum Vaccin Immunother       Date:  2020-06-12       Impact factor: 3.452

Review 6.  Vaccines for measles, mumps and rubella in children.

Authors:  Vittorio Demicheli; Alessandro Rivetti; Maria Grazia Debalini; Carlo Di Pietrantonj
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

Review 7.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

8.  Reemergence of mumps.

Authors:  Kyong Min Choi
Journal:  Korean J Pediatr       Date:  2010-05-31

9.  Prevalence of antibodies against measles, mumps and rubella in the childhood population in Singapore, 2008-2010.

Authors:  L W Ang; F Y Lai; S H Tey; J Cutter; L James; K T Goh
Journal:  Epidemiol Infect       Date:  2012-09-24       Impact factor: 4.434

10.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2020-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.